Allstate Corp Buys 1,631 Shares of United Therapeutics Corporation $UTHR

Allstate Corp lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 111.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,095 shares of the biotechnology company’s stock after purchasing an additional 1,631 shares during the period. Allstate Corp’s holdings in United Therapeutics were worth $1,508,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth $277,000. Cerity Partners LLC grew its holdings in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its holdings in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.9%

Shares of UTHR stock opened at $556.82 on Friday. The stock has a market cap of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.83 and a beta of 0.60. The stock has a 50-day moving average of $566.51 and a 200-day moving average of $515.84. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $575.40, for a total value of $5,466,300.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $23,311,180.20. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,676,831.88. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 601,473 shares of company stock valued at $337,090,644. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on UTHR shares. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.